HBV-IN-21

• UNSPSC Description:

  HBV-IN-21 (Compound II-8b) is an HBV DNA replication inhibitor with an IC50 of 2.2 µM. HBV-IN-21 can interact HBV 4 capsid protein with good affinity (KD = 60.0 μM)[1].

• Target Antigen:

  DNA/RNA Synthesis; HBV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/hbv-in-21.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=C(CC(C)C)SC(C2=NC=CS2)=N1)NNC3=CC=C(F)C=C3

• Molecular Weight:

  376.47

• References & Citations:

  [1]Jia H, et al. Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. Eur J Med Chem. 2020 Sep 15;202:112495.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2460957-52-0